Lyell Immunopharma vs Virax Biolabs Group
Lyell Immunopharma is the larger business, with $36,000 of revenue in fiscal 2025 against $12,423 for Virax Biolabs Group (2.9 times as much). Virax Biolabs Group grew faster (96.2% against -41.0%). Virax Biolabs Group kept more of each dollar of sales as profit: a net margin of -40439.1% against -762355.6%. Lyell Immunopharma carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Lyell ImmunopharmaLYEL, 2025 | Virax Biolabs GroupVRAX, 2026 |
|---|---|---|
| Revenue | $36,000 | $12,423 |
| Revenue growth | -41.0% | 96.2% |
| Net income | −$274m | −$5.0m |
| Operating margin | -748344.4% | -51515.2% |
| Net margin | -762355.6% | -40439.1% |
| Return on equity | -87.0% | -75.7% |
| Free cash flow | −$151m | −$4.9m |
| Cash | $60.2m | $6.4m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 161 | — |
| Market value | $252m | $613,971 |
| Price vs our value range | — | — |
| Moat score | 12 (Weak) | — |
| Insider trades, 12 months | 2 buys, 29 sales | 0 buys, 0 sales |